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Abstract The Weld of tumor vaccination is currently
undergoing a shift in focus, from individualized tailor-made
vaccines to more generally applicable vaccine formula-
tions. Although primarily predicated by Wnancial and logis-
tic considerations, stemming from a growing awareness
that clinical development for wide-scale application can
only be achieved through backing from major pharmaceuti-
cal companies, these new approaches are also supported by
a growing knowledge of the intricacies and minutiae of
antigen presentation and eVector T-cell activation. Here,
the development of whole-cell tumor and dendritic cell
(DC)-based vaccines from an individualized autologous
set-up to a more widely applicable allogeneic approach will
be discussed as reXected by translational studies carried out
over the past two decades at our laboratories and clinics in
the vrije universiteit medical center (VUmc) in Amsterdam,
The Netherlands.
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Autologous whole-cell tumor vaccination
Autologous tumor cells are an obvious source of tumor-
associated antigens (TAA) for vaccination purposes, since,
by deWnition, all relevant candidate TAA should be con-
tained within them. Vaccination with irradiated tumor cells
has been studied in various animal models as early as the
1970s. Pioneered by Hanna et al. irradiated hepatocellular
carcinoma cells were used as a vaccine in a guinea pig
model and, admixed with bacillus calmette-guérin (BCG)
as an immune adjuvant, were found to generate protective
immunity against subsequent challenge with syngeneic
non-irradiated tumor cells [17, 18]. Of note, these early
guinea pig studies revealed the importance of vaccinating
with live tumor cells, suggesting either a) the direct
involvement of the tumor cells themselves in antigen pre-
sentation or b) the importance of prolonged expression and
release of TAA to allow for suYcient uptake by and activa-
tion of immune eVector cells. Before general acceptance of
the concept of cross-priming, the former was actually
regarded as the more obvious explanation.
Colorectal cancer
Building on this pre-clinical work, Hoover et al. conducted
a clinical trial in which patients with stage II/III colorectal
cancer were vaccinated with irradiated autologous tumor
cells and BCG, randomized versus surgery alone [24]. Sub-
group analysis revealed signiWcant overall and disease-free
survival for vaccinated patients. In addition, delayed type
hypersensitivity (DTH) reactions to autologous tumor cells
suggested the presence of tumor-speciWc immunity. Side
eVects were minimal and consisted mostly of ulceration of
the vaccination sites caused by the BCG adjuvant.These
promising results prompted the initiation of a large phase
This article is a symposium paper from the conference “The European 
Society for Medical Oncology (ESMO) and the European Society for 
Cancer Immunology and Immunotherapy (ESCII) International 
Symposium on Immunology”, held in Athens, Greece, on 15–17 
November 2007.
T. D. de Gruijl · A. J. M. van den Eertwegh · H. M. Pinedo
Division of Immunotherapy, Department of Medical Oncology, 
Vrije Universiteit medical Center, Amsterdam, The Netherlands
R. J. Scheper (&)
Department of Pathology, Vrije Universiteit Medical Center, 
De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
e-mail: rj.scheper@vumc.nl123
1570 Cancer Immunol Immunother (2008) 57:1569–1577III study of stage II/III colon cancer patients conducted
under the auspices of the eastern cooperative oncology
group (ECOG) [20]. This study diVered from the Hoover
study in that, due to the large number and wide geographic
distribution of participating sites, each site manufactured its
own vaccines. In an intent-to-treat analysis of all random-
ized patients, no signiWcant diVerences were observed
between the two treatment arms in time to recurrence or
overall survival. In the ECOG study, 12% of all vaccines
failed to meet quality control speciWcations (in terms of cell
number and/or viability), and 15% of the vaccinated
patients failed to develop DTH reactions to tumor cells
alone. Importantly, DTH reactivity to autologous tumor
cells did correlate with survival [20]. It was therefore
assumed that poor quality of a part of the vaccines and var-
iability introduced by manufacture at diVerent sites were at
the root of the disappointing clinical results of this study.
Indeed, survival analysis of patients who were treated with
vaccines that met standardization criteria and who actually
developed anti-tumor immunity (as determined by DTH
reactivity) did show a signiWcant improvement in overall
survival. These Wndings underlined the necessity of stan-
dardized vaccine manufacture to make any meaningful
comparisons in outcome between vaccinees: a particular
challenge in an autologous set-up.
A third phase III study was conducted at our laboratory
in the VUmc, involving 254 patients with stage II/III colon
cancer [62]. This pivotal study diVered from the previous
ECOG study in that a centralized manufacturing laboratory
(i.e.the VUmc) supported the 12 participating hospitals,
resulting in 98% quality approved vaccines and a rate of
97% measurable DTH reactivity upon vaccination (i.e. >5
mm). In an intent-to-treat analysis, autologous tumor cell +
BCG vaccination signiWcantly reduced the rate of disease
recurrence by 44% in patients with stage II/III colon cancer,
but the overall survival was not signiWcantly aVected. A
larger impact was apparent in stage II disease, where a 61%
risk reduction for recurrences and a trend toward improved
overall survival was observed. These data clearly indicate
that the centralized and routine manufacture of quality-
controlled vaccines is of the utmost importance for the
performance of a successful immunization trial.
A meta-analysis was performed which included the
above described three randomized trials for colorectal can-
cer [19]. In the intent-to-treat meta-analysis of all 723
patients who received either a three- or a four-vaccine regi-
men, recurrence-free survival was signiWcantly improved
by autologous whole-cell tumor vaccination. However, no
signiWcant overall survival beneWt could be demonstrated.
While these studies showed promise, more recent FDA
prerequisites have complicated the production and quality
assurance of these autologous whole-cell tumor based vac-
cines for colon cancer. Particularly sterility requirements
are posing a considerable challenge for an autologous
whole-cell vaccine derived from an organ as rife with com-
mensal bacteria as the colon. These restrictions were
enforced despite the fact that empirically, in over 200 vac-
cinated patients, these colon-associated bacteria (whether
admixed with BCG or not) were never found to cause any
untoward side eVects. These regulatory hurdles, combined
with Wnancial restraints, have led to the premature termina-
tion of a Phase III trial carried out in our clinics at the
VUmc, studying the eVect of whole-cell colon tumor vacci-
nation combined with 5-FU chemotherapy versus chemo-
therapy only, in patients with Stage III colon cancer.
Melanoma
Fostering the autologous whole-cell vaccine + BCG
approach, a clinical study was performed at the VUmc
with 81 stage III/IV metastatic melanoma patients [1].
Forty-nine of these patients had no sign of residual disease
after metastasectomy, although the chances of tumor
recurrence were considered high. After metastasectomy
whole-cell tumor vaccines were produced of the resected
tumor tissue. One month after surgery the Wrst of three
weekly administered irradiated vaccines was administered
intradermally in one of the lower extremities. In patients
with evidence of disease during the vaccination period
(n = 38) no clinical responses occurred and no survival ben-
eWt was apparent when compared to historical controls. In
patients without evidence of disease (stage III, n = 35 and
stage IV, n = 14), the 5-year overall survival rate approxi-
mated 45%, which was superior to historical controls (at
35% and 20% for Stage III and IV, respectively) [1]. In
addition, DTH reactivity to tumor cells was found to corre-
spond positively with overall survival [1]. Finally, this
study revealed that the size of DTH-reactions waned after
consecutive non-BCG-containing vaccinations, even in
patients that after a follow-up period of over Wve years
proved to be free of melanoma. This observation strongly
suggests that booster vaccinations can only be eVective
when co-administered with an immunostimulating adju-
vant.
Berd et al. also developed and clinically tested an autolo-
gous melanoma cell vaccine, haptenated with dinitrophenyl
(DNP), and also combined it with BCG as adjuvant [3].
After an inclusion period of more than 10 years they
reported a 5-year relapse free survival of 33% and an over-
all survival of 44% for a non-randomized trial with 214
enrolled stage III melanoma patients. These survival rates
were considered superior to historical control survival data.
Of note, they also observed an association of overall sur-
vival and disease free survival with the induction of DTH
reactivity to unmodiWed (non-haptenated) autologous mela-
noma cells [3].123
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In a large multi-center Phase III trial carried out in Ger-
many, 558 patients with a renal cell tumor were pre-opera-
tively randomized to receive either six monthly intradermal
autologous tumor vaccines or no adjuvant therapy [30].
Tumor cells were pre-treated with IFN- to upregulate
MHC levels and underwent six freeze-thaw cycles prior to
administration. No further immune adjuvants were added to
the vaccines. 5-year progression-free survival was 77.4%
in the vaccinated patients as compared to 67.8% in the
untreated patients. Although promising, these results might
have been improved upon through the inclusion of a strong
immune adjuvant in the vaccine formulation. Although
BCG proved its worth as immune adjuvant, the resulting
ulcers at vaccination sites eventually disqualiWed it as the
adjuvant of choice for cancer vaccination. The identiWca-
tion of hypomethylated CpG sequences derived from bacte-
rial DNA as the immune-activating component of BCG
[31, 32] led to the design of a Phase II trial at the VUmc
in which patients with advanced Renal Cell Cancer were
vaccinated with an autologous whole-tumor cell vaccine
admixed with a combination of CpG (type-B, PF-3512676),
IFN, and Granulocyte-Macrophage Colony-Stimulating
Factor (GM-CSF) as adjuvant. The Wrst three induction
vaccinations were given weekly followed by subcutaneous
administration of IFN- (6 MIU) and PF-3512676 (8 mg bi-
weekly). After 3 months tumor evaluation was performed
and in case of a remission or stable disease patients contin-
ued with 3 monthly vaccinations and PF-3512676/IFN-.
This vaccination schedule resulted in a 20% clinical
response rate in association with a strong anti-tumor DTH
skin reactivity [59]. This study clearly showed the equiva-
lence of this adjuvant combination to BCG in terms of
immune activation, without the ulcer formation usually
associated with BCG.
GVAX: from autologous towards allogeneic tumor 
vaccination
GM-CSF is a 23-kDa glycoprotein that was initially devel-
oped for its activity as a hematopoietic growth factor [52].
Subsequent studies revealed its interesting immunological
features [8, 10]. GM-CSF can overcome tumor-induced
immune suppression and promotes the recruitment and
maturation of specialized antigen-presenting cells (APC).
GM-CSF-mediated activation of APC results in upregula-
tion of MHC class II, co-stimulatory molecules and cyto-
kine production. It increases antibody responses and
cellular immunity after immunization.These combined fea-
tures have made GM-CSF the most commonly used cyto-
kine to boost anti-tumor immunity [8, 10, 29]. In a murine
melanoma model DranoV et al. demonstrated the potency
of prophylactic GM-CSF-transduced autologous tumor cell
vaccines in prevention of tumor outgrowth [9]. Based on
this preclinical work, autologous melanoma tumor cells,
transduced with GM-CSF (GVAX), were applied clinically
and shown to induce tumor-speciWc immunity and durable
anti-tumor responses in a number of trials [22].
Mouse studies clearly demonstrated the eYcacy of
GVAX to depend on the cross-presentation of vaccine-
derived TAA to speciWc cytotoxic T lymphocytes (CTL) in
vivo [22]. This process of cross-priming is facilitated by the
activation of professional APC, the so-called Dendritic
Cells (DC), by GM-CSF. This Wnding led to the realization
that allogeneic cells would also present a viable source of
TAA, which would be taken up by DC and then presented
in the context of appropriate MHC alleles to autologous
CTL. Advantages to the use of allogeneic cells are obvious:
(1) through the use of antigenically well-deWned cell lines
one has access to a sustained and virtually limitless source
of TAA, (2) the use of cell lines allows for the highly stan-
dardized and large-scale production of allogeneic vaccines,
(3) the use of a single batch of allo-vaccines for all vaci-
nees, independent of HLA haplotype, eliminates variability
in the quality and composition of the vaccines and facili-
tates reliable comparative analysis of clinical outcome, and
(4) eliminating the need for the continuous production of
tailor-made individual vaccines simpliWes the logistics and
reduces the laboriousness of the vaccine production and
delivery process and increases its cost-eVectiveness.
Taking these considerations into account, autologous
GVAX approaches have been replaced by allogeneic GVAX
formulations. JaVee et al. tested an allogeneic pancreatic
cancer vaccine as an adjuvant therapy after pancreaticoduo-
denectomy in a phase I dose-escalating study and found no
noteworthy toxicity, while some patients showed increased
DTH-skin reactivity to autologous tumor cells, indicative of
the generation of relevant anti-tumor immunity [28].
Prostate cancer
Michael et al. showed the feasibility of allogeneic prostate
cancer vaccination: vaccines consisting of three prostate
tumor cell lines were i.d. injected monthly over the course
of a year in patients with hormone refractory prostate can-
cer [35]. The Wrst two vaccines were admixed with BCG.
Decreases in PSA velocity were observed in 11/26 patients
with an overall median time to disease progression of 58
weeks as compared to 28 weeks in historical controls. Inter-
estingly, while non-responders showed a mixed Th1/Th2
response upon restimulation with a vaccine lysate, respond-
ers showed a Th1 cytokine release proWle.
Prostate GVAX consists of two prostate cancer cell lines,
LNCaP and PC-3, each of which has been genetically modiWed123
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transduced cell lines, the cells are lethally irradiated to pre-
vent further cell division upon vaccination. In phase I/II
studies the vaccine was generally well tolerated and demon-
strated anti-tumor activity [11, 44, 46]. The largest of these
was a multi-center phase I/II trial in 55 patients with HRPC
[46]. Thirty-four patients with metastases showed an overall
median survival of 26 months, which compares favorably
with median survival times observed in phase II taxane che-
motherapy trials in similar patients with HRPC [37, 42, 46].
Induction of sero-immune reactivity against the prostate
cancer cells was demonstrated by Western blot. A smaller
phase I/II trial was carried out in hormone therapy-naive
patients with a prostate-speciWc antigen (PSA) relapse fol-
lowing radical prostatectomy and absence of radiological
metastases [44]. Treatments were administered weekly via
intradermal injections of Prostate GVAX for 8 weeks.
Twenty-one patients were enrolled and treated. Toxicities
included local injection-site reactions, pruritus, and Xu-like
symptoms. At 20 weeks post Wrst treatment, 16 of 21 (76%)
patients showed a statistically signiWcant decrease in PSA
velocity compared with pre-vaccination (P < 0.001) [44].
Clinical eYcacy of Prostate GVAX is currently tested in
metastatic prostate cancer patients in two phase III random-
ized studies (VITAL-1 and -2). In the Wrst study GVAX is
compared to Docetaxel plus prednisone and in the second
study GVAX in combination with docetaxel is compared to
docetaxel alone. The results are eagerly awaited.
While GVAX monotherapy has shown moderate clinical
eYcacy, this may be improved upon through interference
with checkpoints at the T-cell level that under normal
circumstances serve to reinforce tolerance but that in
tumor-conditioned environments may suppress appropriate
anti-tumor immune responses. The CTL Antigen-4 (CTLA-4)
receptor represents such a crucial checkpoint [12]. It is
expressed on activated T-cells and binds to CD86 and
CD80 on DC with higher avidity than its competitor ligand
CD28. In contrast to CD28, CTLA-4 relays inhibitory sig-
nals to the T cell and blocks activating signals originating
from CD28-CD86/CD80 interactions. CTLA-4 blockade
breaks through inhibitory feedback loops in tumor-speciWc
T-cells and may thus lead to expansion of eVector CTL
with possibly a higher functional avidity [12]. In mouse
tumor models, the combination of GM-CSF-secreting vac-
cines and CTLA-4-blocking antibodies has resulted in
improved anti-tumor immunity and protection from tumor
outgrowth. Both in the B16 melanoma model and in
TRAMP, a transgenic murine model of spontaneously aris-
ing prostate cancer, the administration of either anti-CTLA-
4 mAbs or vaccination with GM-CSF transfected tumor
cells had minimal to no eVect on tumor rejection. In marked
contrast, treatment with the combination of anti-CTLA-4
and GM-CSF-transduced tumor cells at the time of tumor
inoculation signiWcantly reduced tumor incidence [26, 60,
61]. This anti-tumor eVect was shown to be CTL-mediated
and T helper cell (Th) independent, and indicates that
CTLA-4 blockade can lower the threshold of required acti-
vating signals such that Th-mediated activation of DC is no
longer needed for the provision of a “license to kill” to CTL
[61]. While Phase I/II clinical trials studying monotherapy
with either Prostate GVAX or anti-CTLA-4, have shown
feasibility of treatment with either modality without severe
side-eVects and with modest signs of possible clinical
eYcacy [11, 44, 46, 47], the aforementioned pre-clinical
studies clearly demonstrated a potentially increased
eYcacy of anti-CTLA-4 as part of a combinatorial
approach with Prostate GVAX. This led to the initiation of
a Phase I clinical study in the VUmc, in which chemo-naive
patients with metastatic hormone refractory prostate cancer
(HRPC) receive the allogeneic prostate GVAX immuno-
therapy combined with infusions of ipilimumab/anti-
CTLA-4. This trial represents the Wrst clinical application
of the GVAX/anti-CTLA4 combination. In the dose escala-
tion part of this trial, the combination of GVAX immuno-
therapy with high doses of ipilimumab (3 or 5 mg/kg) has
led to promising clinical results with some clear PSA
responses [16]. The trial has now entered its expansion
phase with an accrual of 16 patients to be treated at the
MTD of ipilimumab, determined in the escalation phase to
be 3 mg/kg. To demonstrate immune eVects of this treat-
ment and possibly correlate these with clinical eYcacy, we
are extensively monitoring dendritic and T-cell functions.
The results may aid in the rational design of clinical follow-
up studies. Final analysis will be performed after conclud-
ing the expansion phase of this Phase I trial.
DC-based tumor vaccination: the case for an allogeneic 
source of DC
DC are uniquely able to initiate primary immune responses.
Myeloid DC diVerentiate from CD34+ hematopoietic pro-
genitor cells (HPC) and can develop into two recognized
subsets, Langerhans Cells (LC, expressing the characteristic
C-type Lectin Langerin and containing Birbeck Granules
[BG]), which are mostly found in stratiWed epithelia, and
Interstitial DC (IDC, expressing the C-type Lectin DC-
SIGN), which are mostly located in connective tissues.
Because of their critical role in orchestrating the immune
response, DC are now widely applied in vaccines for the
treatment of cancer [4]. So far, the vast majority of clinical
vaccination trials utilized Monocyte-derived DC (MoDC,
i.e. IDC equivalents), while only few trials have made use of
DC derived from CD34+ precursors (CD34-DC [4]). Never-
theless, it has been suggested that CD34-DC are more eVec-
tive anti-tumor T-cell inducers than MoDC, both in vitro and123
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eVect might be due to “contaminating” LC in the CD34-DC
preparations [38]. DC may be pulsed with TAA-derived epi-
topes in various ways: through loading with proteins or pep-
tides, through incubation with tumor lysates or apoptotic
bodies, through fusion with tumor cells, through transfection
with DNA or RNA, or through viral transduction. In various
trials anti-tumor immunity as well as clinical eYcacy of DC-
based tumor vaccination have been reported, particularly for
melanoma [33]. So far, wide-scale implementation has
proven to be unattainable for any of the tested DC-based
vaccines. A case in point was recently provided by sipuleu-
cel-T (APC8015), which consists of a DC-like fraction
enriched from autologous peripheral blood, pulsed with a
prostate TAA/GM-CSF fusion protein. Despite a favorable
survival beneWt in a randomized Phase III trial of 225
patients with metastatic prostate cancer [45] and an initial
positive verdict on safety and clinical eYcacy from an FDA
advisory committee, it was denied FDA approval, just fall-
ing short of becoming the Wrst FDA-approved cell-based
vaccine product [15]. The FDA decision letter called for
additional proof of clinical eYcacy from an ongoing ran-
domized Phase III trial (a new interim analysis of which is
expected mid-2008) and more detailed information on the
manufacturing process [15, 63]. Certainly, multiple hurdles
are to be taken in the development of such autologous DC
precursor-based immunotherapies as they are: (a) hard to
standardize, resulting in highly variable results, complicat-
ing the evaluation of clinical trials, and often resulting in
negative clinical trial outcomes, (b) laborious and time con-
suming, and therefore c) very expensive [33]. These draw-
backs have thusfar precluded wide-scale application of
autologous DC-based vaccines. In addition, although
conXicting reports exist on this matter, there have been
indications for an inferior T-cell-stimulatory phenotype of
DC derived from advanced cancer patients [21, 36], which
would also argue against the use of autologous DC.
An alternative approach which has recently been
explored is the use of allogeneic DC as vaccine vehicles. A
major advantage of the use of alloDC is the feasibility of
preparing large clinical-grade batches that may be used for
all patients, thus providing a more standardized DC vaccine
in terms of phenotype and maturation status. As with allo-
geneic tumor cell-based vaccines, bypassing the need for
individually prepared vaccines represents a considerable
logistic advantage. Although seemingly counter-intuitive,
from a theoretical point of view alloDC-based vaccines
might even induce a stronger vaccine-speciWc immune
response than autoDC [13]. Since an estimated 1–10% of
the circulating T cell repertoire is directed against allo-anti-
gens, alloDC may be expected to trigger a broadly reactive
T-cell response with two possible advantages: (1) activa-
tion of tumor-reactive T-cells through fortuitous cross-reac-
tivity and (perhaps more likely and more importantly:) (2)
allo-antigens on the DC may provide T helper (Th) epitopes
aiding in the optimal activation of Cytotoxic T Lympho-
cytes (CTL) against the tumor-related vaccine payload [13].
Several mouse studies have compared the use of alloDC
versus syngeneic DC as fusion partners for syngeneic tumor
cells, creating a DC-tumor hybrid vaccine, and consistently
shown equal or even superior protection against tumor
outgrowth with alloDC [43, 48, 51, 58]. The anti-tumor
responses were mostly shown to be CTL-mediated. Mecha-
nistically, observed advantages of the use of alloDC hybrids
seemed to be related to skewing towards a type-1 cytokine
response as compared to the use of syngeneic DC [43, 48, 58].
Various clinical trials have been carried out to validate
the use of alloDC-based tumor vaccination and results so far
have been mixed [23, 27, 36, 50, 55–57]. In these studies
patients with metastatic RCC, with melanoma, or with early-
stage B-cell chronic lymphocytic leukemia were vaccinated
with alloDC, either loaded with tumor lysates or apoptotic
bodies, or fused to autologous or allogeneic tumor cells. All
studies showed the tolerability and safety of this approach,
with some partial clinical responses, accompanied by evi-
dence of tumor-speciWc T-cell activation. On the whole,
alloDC based vaccines appeared less eVective than autolo-
gous DC used in previous trials. This might be due to a lack
in HLA class I matching [55, 56]. Of note, most favorable
results in murine models were obtained with “semi-alloge-
neic” DC, i.e. alloDC that were partially MHC-matched
[58]. While allo-MHC class II molecules may provide bene-
Wcial Th activity, it is likely that for a CTL response to be
induced, at least partial MHC class I matching is required.
This was recently conWrmed by a vaccination study in colo-
rectal cancer patients, showing that tumor lysate-loaded DC
with one haplotype miss-match induced stronger anti-tumor
immune responses, accompanied by stabilized or reduced
CEA serum levels, as compared to fully autologous DC [50].
Similarly, vaccination with autologous melanoma/alloDC
hybrids, which per deWnition would present TAA peptides in
the context of matched (in this case autologous) HLA class I
molecules, resulted in clinical responses, long survival
times, and high-frequency post-vaccination T cell responses
against a broad range of melanoma epitopes [55, 57]. These
studies clearly demonstrate the feasibility of generating
TAA-speciWc T-cell responses in vivo on an allo-back-
ground: anti-tumor responses were quite clearly not
drowned out by collateral allo-T-cell responses.
The MUTZ-3 cell line: a sustainable source of alloDC 
for vaccination purposes
While CD34-DC may be more powerful vaccine vehicles
than the more commonly used MoDC, the use of in vitro123
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laborious methodologies involved, considerable functional
and phenotypic variability between batches (both intra- and
inter-individual) and the extremely low frequency of
CD34+ DC precursor cells in peripheral blood. A human
CD34+ DC line would be an attractive alternative, allowing
the preparation of large quantities of standardized alloDC
that would provide an oV-the-shelf alternative for autolo-
gous DC-based tumor vaccination purposes. Over the past 8
years we have gathered evidence that the cytokine-depen-
dent CD34+ human acute myeloid leukemia (AML) cell
line MUTZ-3 represents such a sustainable supply of DC
[34, 39–41]. By matching for the HLA-A2 and/or -A3 alle-
les (both present on MUTZ–3), >50% of patients should be
eligible for MUTZ-3-based vaccination regimens.
MUTZ-3 is a heterogeneous AML cell line consisting of
CD34+ and CD14+ cell populations [25]. CD34+ MUTZ-3
cells behave as the immortalized equivalents of CD34+ DC
precursor cells [34, 40]. Upon stimulation with speciWc
cytokine cocktails, CD34+ MUTZ-3 progenitors pass
through a CD14+ state, lose their proliferative capacity, and
acquire a phenotype consistent with either classic IDC or LC
with respective characteristic and mutually exclusive
expression of DC-SIGN or Langerin and Birbeck Granules
[40]. MUTZ3-DC display the full range of functional MHC-
and CD1d-mediated antigen processing and presentation
pathways and upon maturation (induced by cocktails com-
prising IL-6, PGE2, TNF-, IL-1, IFN-, or Poly:IC) up-
regulate co-stimulatory molecules, express CD83, and dis-
play an enhanced allogeneic T-cell priming ability in mixed
leukocyte reactions (MLR) [34, 40]. By extensive functional
characterization of MUTZ3-DC (diVerentiated to either IDC
or LC), we aimed to elucidate their ability to induce a spe-
ciWc T-cell response and to serve as a clinical vehicle of
tumor vaccines [39, 41]. The lymph node (LN) homing
potential of MUTZ3-DC was conWrmed in a trans-well
assay in response to the LN-derived chemokines CCL19 and
CCL21 and shown to be comparable to MoDC [41]. This is
in line with their CCR7 expression and suggestive of their in
vivo ability to reach the paracortical T-cell areas of LN. We
demonstrated that functional (i.e. tumor-recognizing) CTL
clones could be generated against multiple tumor-associated
epitopes (derived from MART-1, CEA, Her-2/neu, and
PSA) by stimulating CD8+ CTL precursors with peptide-
loaded allogeneic, HLA-A2-matched MUTZ3-DC (both
IDC and LC) [39, 41]. Importantly, a consistent induction
capacity, as determined by MHC tetramer (Tm) binding,
was found in multiple donors (i.e. across a range of allo-
MHC haplotypes) and at an eYciency comparable to autolo-
gous peptide-loaded MoDC. TAA-speciWc CTLs generated
by MUTZ3-DC were of low-to-intermediate functional
avidity. Retroviral transduction with IL-12p70 signiWcantly
improved CTL priming eYciency of both MUTZ-3-derived
IDC and LC and resulted in priming of MART-1 speciWc
CTL with higher functional avidity, a more deWned mem-
ory-eVector phenotype, and a higher cytolytic potential for
MART-1-expressing melanoma cells [41].
Planned clinical trials are expected to demonstrate the
eYcacy of allo-DC cell lines in the in vivo priming of spe-
ciWc eVector T-cells in the face of an ongoing competition
with simultaneously primed allogeneic T-cells. It will be of
particular interest to establish the number of eVective
booster vaccinations that can be administered following the
prime vaccination, before allogeneic responses become too
restrictive and alternative vaccine formulations may have to
be applied in alternating prime-boost approaches.
The future: from whole-cell vaccines to DC-targeted 
vaccines?
While currently explored allogeneic approaches in whole
tumor cell and/or DC-based vaccination procedures repre-
sent an improvement in terms of standardization and cost
eVectiveness over their autologous counterparts, they nev-
ertheless entail the culture of large batches of cells under
cGMP conditions. It is clear that further optimization of
these in vitro culture methodologies is required to improve
therapeutic eYcacy of DC-based vaccines. In order to home
to draining LN and subsequently activate speciWc T cells,
DC have to reach the correct level of activation and display
the correct set of chemokine receptors, expression of which
should be precisely orchestrated, both spatially and chrono-
logically [33]. In vitro generated and readministered DC do
not necessarily fulWll all these requirements, as only very
low numbers of injected DC (typically <1%) reach the
draining lymph nodes [7]. Therefore, next to improving
whole tumor cell and/or DC-based vaccines, direct in vivo
approaches certainly deserve more attention. Of note, many
novel tools have now become available for targeting DC
[49]. In parallel studies, therefore, we currently pursue the
latter approach using DC-targeting adenoviral vectors car-
rying antigenic payloads [5, 6, 54]. At the end of the day,
results from rigidly controlled and comparative clinical
studies should reveal those immunotherapeutic approaches
that deserve inclusion into regular cancer patient care.
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